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result	 of	 public	 health	 initiatives	 and	 advances	 in	 therapeutic	 dis-
coveries.	 Since	 1850,	 life	 expectancy	 has	 advanced	 by	 1	year	 for	
every	four.1	Accompanying	this	change	is	the	rapid	development	of	
anti‐aging	science.	There	are	three	schools	of	thought	in	the	field	of	
aging	 science.	One	perspective	 is	 the	 life	 course	 approach,	which	
considers	that	aging	is	a	good	and	natural	process	to	be	embraced	
as	a	necessary	and	positive	aspect	of	 life,	where	 the	aim	 is	 to	 im-
prove	 the	 quality	 of	 existing	 lifespan	 and	 “compress”	 morbidity.	
Another	view	is	that	aging	is	undesirable,	and	that	rejuvenation	and	
indeed	immortality	are	possible	since	the	biological	basis	of	aging	is	




spectives	 are	 seldom	 discussed	 in	 cross‐disciplinary	 settings.	 This	
article	discusses	some	of	the	key	ethical	 issues	arising	from	recent	
advances	in	biogerontology.
2  | ADVANCES IN GEROSCIENCE
The	biological	basis	of	aging	is	increasingly	understood,	and	myriad	
ways	 of	 altering	 aging	 are	 now	 known.	One	 cause	 of	 aging	 is	 the	
accumulation	 of	 molecular	 damage,	 such	 as	 DNA	 mutations	 and	
misfolded	proteins.	Damage	can	further	lead	to	“meta‐effects,”	such	
as	the	emergence	of	senescent	cells	or	dysfunctional	mitochondria,	
which	contribute	 to	a	 feedback	 loop	of	damage	and	dysfunction.2 
These	deleterious	causes	of	aging	are	offset	by	endogenous	repair	




























international	 consortium	 is	 working	 to	 move	 anti‐aging	 therapies	
more	rapidly	into	clinical	trials.16
3  | TECHNOLOGIC AL ADVANCES
If	maintenance	 of	 function	 rather	 than	 life	 extension	 is	 a	 key	 de-
sirable	outcome	during	 the	aging	process,	 then	 technology	has	an	
important	role	in	achieving	this	goal	in	the	presence	of	physical	dis-
abilities	as	well	as	cognitive	function	impairments.




skeleton	 robotics.	 Robotics	 are	 also	 being	 used	 for	 surgical	 pro-














4  | ETHIC AL PERSPEC TIVES
4.1 | Is aging a disease?
It	 is	 commonly	assumed,	 in	 the	debate	on	 the	ethics	of	 anti‐aging	
research,	that	the	question	of	whether	aging	is	a	disease	or	not	car-
ries	 high	 normative	 significance.	 For	 instance,	 some	 people	 hold	
that	if	(and	only	if)	aging	is	a	disease,	then	it	is	an	appropriate	target	
for	medical	 intervention;	otherwise	 it	 is	not.	On	a	more	pragmatic	
note,	it	seems	clear	that	being	able	to	label	aging	as	a	disease	would	















When	 it	 comes	 to	 establishing	 the	medical	 legitimacy	 of	 anti‐
aging	 interventions,	 it	 might	 be	 possible	 to	 sidestep	 that	 difficult	
























4.2 | Life extension, justice, and equity








older	population.	But	 it	 is	not	clear	that	this	 is	problematic	 if	mor-
bidity	 is	compressed.	Moreover,	 longer	 lives	 increase	the	temporal	
discounting	of	costs,	as	well	as	the	number	of	productive	years.
It	 is	 also	not	evident	 that	extended	 lives	mean	 that	 the	young	
would	unfairly	subsidize	the	old	if	we	adopt	a	whole‐life	perspective	
and	think	in	terms	of	turn‐taking.














Concerns	are	 likely	 to	be	 raised	about	 justice	when	consider-
ing	any	interventions	to	extend	life.	One	source	of	such	concerns	










has	 the	 potential	 to	 either	 reduce	 or	 exacerbate	 their	 impact.	 In	
doing	so	it	can	either	increase	or	decrease	health	inequality.
However,	 inequality	 is	also	 inherently	human.	Some	people	on	
reaching	an	advanced	age	feel	as	though	they	have	already	lived	life	
to	its	fullest,	and	do	not	feel	the	need	to	extend	it	further.	It	may	or	
may	not	be	 that	what	 life	has	 to	offer	 them	 is	not	something	 that	
they	care	to	extend.	The	structural	conditions	of	their	lived	lives	may	
already	have	been	patterned	by	social	inequality	at	a	very	basic	level.
For	 this	 reason,	 assessing	 the	 ethical	 acceptability	 of	 work	 in	
biogerontology	 requires	 taking	account	of	 its	 impact	on	both	 indi-
viduals	and	society.	Doing	so	is	not	easy.	It	requires	answering	three	















4.3 | The good and the bad (misapplications)
Research	 and	development	 in	 the	 field	 of	 anti‐aging	medicine	has	
fueled	 a	 multi‐	 billion	 dollar	 industry	 in	 the	 past	 decade,28	 with	
the	 largest	 proportion	 spent	 on	 integration	 of	 large	 omics	 data-









dietary	supplements)	 instead	of	changing	behavior	 to	 lead	healthy	
lifestyles,	even	though	there	is	ample	evidence	of	the	health	benefits	
of	the	latter.	The	recent	case	of	gene	editing	of	an	implanted	human	
embryo	 in	a	private	 facility	 illustrates	how	regulatory	mechanisms	
have	failed	to	keep	pace	with	activities	in	these	fields,	even	though	
there	have	been	widespread	discussions	on	the	ethical	perspectives	
of	 gene	 editing,	 where	 there	 remains	 uncertainty	 regarding	 long	
term	side‐effects	of	irreversibly	altering	the	human	germ	cell	line.29
4.4 | Issues relating to artificial 
intelligence and robotics
Various	ethical	 issues	need	 to	be	 flagged	up	 relating	 to	 the	above	
developments.	 The	 use	 of	 robotic	 surgical	 techniques	 needs	 to	
be	 regularly	 audited	 to	 evaluate	 performance	 and	 complications.	
Similar	 data	 are	 needed	 for	 service	 and	 companion/social	 robots.	
Widespread	 use	will	 depend	 on	 cost‐benefit	 analyses,	which	may	
guide	 governments	 to	 decide	 on	 financing,	 and	 this	will	 raise	 de-
bates	regarding	prioritization	in	health	care	and	issues	of	justice,	as	
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